Eloralintide vs Cagrilintide

This article is for informational and educational purposes only and does not constitute medical advice. Eloralintide and cagrilintide are supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and are not approved by the FDA for human or veterinary use. Both are investigational compounds; neither is an approved medicine.

Wholesale Peps is not affiliated with, endorsed by, or connected to Eli Lilly and Company or Novo Nordisk A/S. This comparison is compiled from publicly available peer-reviewed literature and official trial reports for educational purposes only.

1. Eloralintide vs Cagrilintide — Master Comparison Table

The table below summarizes the two compounds across the attributes researchers most often search. Values are drawn from peer-reviewed literature and official trial reports. Because there is no head-to-head study, efficacy figures come from separate trials and are not directly interchangeable; they depend on dose, duration, population, and the statistical estimand quoted. Where a value is uncertain or study-dependent, the table says so rather than implying a false precision.

2. What Is Amylin?

Amylin, also called islet amyloid polypeptide (IAPP), is a 37-amino-acid peptide hormone that pancreatic beta cells co-secrete with insulin in response to eating. The two hormones are released together, and where insulin acts mainly on glucose disposal, amylin governs the pace and volume of nutrient intake. It does this through three complementary actions: it slows gastric emptying so nutrients reach the small intestine more gradually, it suppresses the post-meal rise in glucagon from pancreatic alpha cells, and it signals satiety to the brain to reduce food intake [6].

The satiety signal is central to why amylin is an attractive research target. Amylin acts on receptors concentrated in the area postrema, a brainstem region that lies outside the blood-brain barrier and can sample hormones circulating in the blood. From there the signal propagates to hypothalamic and brainstem circuits that regulate energy balance. Because these are anatomically and pharmacologically different from the circuits GLP-1 recruits, amylin agonism and GLP-1 agonism can add to one another rather than simply overlap, which is the rationale behind combining the two pathways.

Native amylin is not itself usable as a long-acting agent. It has a plasma half-life of only a few minutes, and the human sequence is prone to forming amyloid fibrils that are toxic to beta cells. Every therapeutic amylin analogue therefore has to solve two engineering problems at once: preventing that aggregation and extending the half-life. The first approved amylin agonist, pramlintide, addressed aggregation but still required dosing with each meal. Eloralintide and cagrilintide are the next-generation answers, both engineered for once-weekly dosing. A fuller treatment of amylin receptor biology is provided in the individual cagrilintide research review and eloralintide research review on this site.

3. What Is Eloralintide?

Eloralintide (development code LY3841136) is an investigational amylin receptor agonist from Eli Lilly, engineered for once-weekly subcutaneous dosing in obesity research. Structurally it is a 37-residue amylin analogue in which the native disulfide bond is replaced by a more stable methylene thioacetal bridge, and a C20 fatty-diacid chain is attached at a lysine residue to enable reversible albumin binding. That albumin binding is what stretches its exposure into the once-weekly range [1].

The defining feature of eloralintide is receptor selectivity. Amylin receptors are complexes of the calcitonin receptor with accessory proteins, and eloralintide was designed to favour one of them, AMY1R, over the others. In human in vitro assays it activated AMY1R with an EC₅₀ of roughly 24 pM, about 12-fold more potent than at the calcitonin receptor and about 11-fold more potent than at AMY3R, with a correspondingly higher binding affinity for AMY1R [1]. This is a different design philosophy from the first-generation analogues, which engage amylin and calcitonin receptors more broadly. The intent is to keep the satiety-driving amylin signal while limiting activity the developers consider less useful.

In pharmacokinetic terms, phase-1 human studies reported an elimination half-life on the order of 310 to 366 hours, roughly 13 to 15 days, supporting the once-weekly interval [2]. Eloralintide has moved through phase-1 single-ascending-dose work in healthy volunteers, a 48-week phase-2 trial in adults with obesity or overweight, and combination studies with tirzepatide, and it has now entered phase-3 development under Lilly's ENLIGHTEN program. It remains investigational and has not been approved by any regulatory authority, and phase-3 efficacy results are not yet available. Its clinical research is discussed in section 7.

4. What Is Cagrilintide?

Cagrilintide (also known as AM833) is a long-acting amylin analogue from Novo Nordisk. Like eloralintide it is built on the 37-amino-acid amylin scaffold with substitutions that block amyloid aggregation, and it carries a C18 fatty-diacid chain attached through a short linker to a lysine residue, which enables albumin binding and a plasma half-life of roughly seven days for once-weekly dosing. Its molecular weight is about 4,413 Da.

Where cagrilintide differs from eloralintide is receptor coverage. Cagrilintide is a broad, non-selective agonist: it engages amylin receptor subtypes together with the calcitonin receptor, and is often described as a dual amylin and calcitonin receptor agonist. This broader profile reflects an earlier design generation in which the goal was potent amylin signaling rather than subtype selectivity. Whether the added calcitonin-receptor activity helps, hurts, or is neutral for efficacy and tolerability is one of the open questions the selective approach is meant to probe.

Cagrilintide has been studied both as a standalone agent and, more prominently, as one half of CagriSema, a fixed-dose combination with the GLP-1 receptor agonist semaglutide. As monotherapy in a phase-2 dose-finding trial it produced about 10.8 percent mean body-weight reduction at 26 weeks [4]. As CagriSema it completed the phase-3 REDEFINE program, and Novo Nordisk submitted CagriSema to the FDA in December 2025, with a regulatory decision anticipated in late 2026 [7]. CagriSema and the reasoning behind combining amylin with GLP-1 are covered in section 10.

5. Eloralintide vs Cagrilintide: Mechanism of Action

The most important mechanistic distinction between these two compounds is selectivity across the amylin receptor family. Understanding it requires a short note on how amylin receptors are built. There is no single "amylin receptor" protein. Instead, the calcitonin receptor (CTR) pairs with an accessory receptor activity-modifying protein (RAMP) to form a complex with amylin sensitivity. CTR with RAMP1 forms AMY1R; CTR with RAMP3 forms AMY3R; CTR on its own responds to calcitonin. These share a subunit, so a compound's balance of activity across CTR, AMY1R, and AMY3R depends on fine structural details.

Eloralintide was engineered to be selective for AMY1R. In human assays it favoured AMY1R by roughly an order of magnitude over both the calcitonin receptor and AMY3R [1]. The working hypothesis is that AMY1R is the complex most responsible for amylin's central satiety effects, so a compound biased toward it might drive appetite reduction while engaging the calcitonin receptor as little as possible.

Cagrilintide takes the opposite approach by design. It activates amylin receptor subtypes broadly and engages the calcitonin receptor as well. This wider coverage still produces strong satiety signaling and clinically meaningful weight reduction, and it is the profile that carried the amylin class into phase-3 development. The two compounds therefore represent a genuine contrast in strategy: a targeted, single-subtype agonist versus a broad-spectrum one.

A crucial caution: selectivity is a mechanistic difference, not automatically a clinical advantage. It is tempting to read "selective" as "better," but receptor selectivity does not by itself predict superior weight loss, better tolerability, or a safer profile. Whether eloralintide's AMY1R focus yields a real clinical benefit over cagrilintide's broader coverage can only be answered by data, and the relevant head-to-head data do not exist. What follows in the clinical sections describes what each compound has shown in its own trials, not what a direct contest would show.

6. Pharmacokinetics and Half-Life

Both compounds are engineered around the same problem: native amylin lasts only minutes, so a once-weekly analogue needs a way to resist rapid clearance. Both solve it with a fatty-diacid chain that binds reversibly to circulating albumin, keeping the peptide in the bloodstream and shielding it from renal filtration and proteolysis. The difference is in the details of the chain and the resulting exposure.

The published human half-life for eloralintide, roughly 13 to 15 days, is longer than the roughly seven days reported for cagrilintide. Both comfortably support once-weekly administration, and a longer half-life is not inherently better; it mainly affects how quickly steady state is reached and how gradually exposure falls after the last dose. These figures come from separate development programs measured under different conditions, so they should be read as characterising each compound rather than as a precise ranking. In vitro, both are supplied as lyophilized powder and studied under buffer conditions that do not reproduce the albumin binding and distribution of systemic dosing, a caveat that applies to any receptor or signaling assay run on either compound.

7. Human Clinical Research

7.1 Eloralintide Clinical Research

Eloralintide's first-in-human work was a phase-1, randomized, placebo-controlled single-ascending-dose study in healthy participants across a wide dose range. It established the once-weekly pharmacokinetic profile and an early tolerability picture consistent with the amylin class, with gastrointestinal effects as the main finding; a single 12 mg dose produced about a 4.4 percent mean body-weight reduction by week 4 versus a slight gain on placebo [2].

The key efficacy readout is a 48-week phase-2 trial in 263 adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes, conducted across US sites and reported at ObesityWeek 2025 [3]. Participants were randomized to placebo or to eloralintide at 1, 3, 6, or 9 mg, or to dose-escalation arms. On the efficacy estimand, mean body-weight reductions rose with dose: roughly 9 percent at 1 mg, 12 percent at 3 mg, 18 percent at 6 mg, and about 20 percent at 9 mg, compared with roughly 0.4 percent on placebo. All active arms met the primary endpoint. Notably, the lower-dose arms reported adverse-event rates close to placebo, which is the kind of observation the selectivity hypothesis predicts, though a single trial cannot confirm the mechanism behind it. Eloralintide has also been studied in combination with tirzepatide in phase-2 trials that have completed enrollment, and the amylin-plus-incretin strategy has since advanced into phase 3, discussed in section 13.

The main limitations are stage and publication depth. Eloralintide has completed phase 2 and has now entered phase-3 development (the ENLIGHTEN program), although phase-3 efficacy results are not yet available; there are no long-term or cardiovascular-outcome data; and full peer-reviewed detail, such as complete responder and subgroup analyses, is only now entering the literature. Its evidence base is younger than cagrilintide's.

7.2 Cagrilintide Clinical Research

Cagrilintide has a longer clinical trail. As monotherapy, a phase-2 dose-finding trial reported about 10.8 percent mean body-weight reduction at the highest dose over 26 weeks [4], establishing amylin agonism as a viable standalone weight-management mechanism. Its most consequential data, however, come from the combination.

As CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg), cagrilintide advanced into the phase-3 REDEFINE program. In REDEFINE 1, a 68-week trial in adults with obesity or overweight without type 2 diabetes, CagriSema produced about 20.4 percent mean body-weight reduction on the treatment-policy estimand, rising to about 22.7 percent assuming full adherence, versus roughly 3 percent for placebo; for reference within the same trial, cagrilintide alone reached about 11.5 percent and semaglutide alone about 14.9 percent [5]. In REDEFINE 2, which enrolled people with type 2 diabetes, CagriSema achieved about 15.7 percent at 68 weeks versus about 3.1 percent on placebo. The program also includes a cardiovascular-outcomes trial and longer-duration studies that were still ongoing as of this review.

Cagrilintide's limitations are of a different kind. Because its headline results come from the combination product, the specific contribution of cagrilintide within CagriSema is inferred from the component arms rather than isolated directly, and long-term cardiovascular-outcome data were not yet available at the time of writing. Its regulatory application is under FDA review, with a decision anticipated in late 2026, and it is not yet approved.

Placing these programs beside one another highlights why a direct comparison is difficult. Eloralintide's roughly 20 percent figure is a monotherapy result at 48 weeks; CagriSema's roughly 20 percent figure is a combination result at 68 weeks that includes a GLP-1 agonist. Cagrilintide's own monotherapy figure, about 10.8 percent, came from a shorter 26-week study. Cross-trial comparison across different regimens, durations, and estimands has real limits, which the chart below is drawn to illustrate rather than to declare a winner.

8. Eloralintide vs Cagrilintide for Weight-Related Research

The published clinical evidence points in a consistent direction for the class: amylin receptor agonism reduces appetite and energy intake and produces dose-dependent body-weight reduction. Both compounds show this pattern within their own trials. Eloralintide's phase-2 data show a clear dose-response up to about 20 percent at 48 weeks as monotherapy; cagrilintide contributes meaningfully within CagriSema, whose combination result reached about 20 percent at 68 weeks, and reached about 10.8 percent on its own over 26 weeks.

What the evidence does not support is a ranking. There is no direct head-to-head trial, so any claim that one compound produces more weight change than the other would be an inference across studies that differ in almost every design variable. The most defensible reading is narrow: eloralintide has demonstrated that a selective AMY1R agonist can reach roughly 20 percent weight reduction as a standalone agent in phase 2, and cagrilintide has demonstrated, at phase 3, that a broad amylin analogue paired with a GLP-1 agonist can reach a similar figure. These are complementary data points about the amylin approach, not a contest between the two molecules.

9. Side Effects Observed in Clinical Studies

Across the amylin class, the adverse events reported in clinical studies are predominantly gastrointestinal, and both compounds fit that pattern. Effects reported in the published and reported trials include nausea, vomiting, diarrhea, constipation, and reduced appetite, generally most frequent during dose escalation and typically mild to moderate. Injection-site reactions are reported for subcutaneous peptides of this kind. These are effects observed in studies, not guaranteed outcomes, and their frequency depends heavily on dose and titration schedule.

The tolerability question that most distinguishes the two compounds is whether eloralintide's AMY1R selectivity produces a cleaner gastrointestinal profile. Two threads of evidence bear on this, and neither is decisive. In eloralintide's phase-2 trial, the lower-dose arms reported adverse-event rates close to placebo, which is consistent with the selectivity rationale [3]. And in Eli Lilly's preclinical discovery work, eloralintide induced less conditioned taste avoidance than cagrilintide in rats [1]. But the first is a within-trial observation at low doses, and the second is an animal finding that does not establish a human difference. The data so far modestly favour the selectivity hypothesis without settling it, and only a head-to-head study could.

10. Where CagriSema Fits In

Cagrilintide is discussed together with semaglutide so often because the two hormones act on complementary pathways. Amylin signals satiety largely through the brainstem and area postrema, while GLP-1 acts on its own receptors in overlapping but distinct circuits and adds glucose-dependent insulin secretion and further appetite suppression. Combining an amylin analogue with a GLP-1 agonist recruits both systems at once, and preclinical and early clinical work suggested the effects could be additive rather than redundant. That is the reasoning behind CagriSema.

CagriSema is the fixed-dose, once-weekly combination of cagrilintide 2.4 mg and semaglutide 2.4 mg. Its phase-3 REDEFINE results, summarized in section 7, are the main reason cagrilintide is the more clinically advanced of the two amylin compounds discussed here. The broader significance is strategic: CagriSema is a leading example of the "amylin plus GLP-1" idea that now shapes much of metabolic drug research. Eloralintide's own combination study, pairing it with tirzepatide, pursues the same logic from the selective-amylin side. This section describes why the combination is of research interest; it is not a guide to using either compound.

11. Why Eloralintide Is Scientifically Interesting

Eloralintide is notable less for its weight-loss numbers than for the question it is built to answer. First-generation amylin analogues engage the amylin and calcitonin receptors broadly, and it has never been clear how much each receptor contributes to the useful effects versus the unwanted ones. By building a compound that is selective for AMY1R, developers create a tool for isolating that contribution in humans.

Several research questions follow directly, and each is currently unresolved:

• Does selectivity change tolerability? If calcitonin-receptor activation drives some of the gastrointestinal burden without adding proportional satiety, a selective agonist might be better tolerated at equivalent efficacy. The low-dose eloralintide data hint at this, but it is unproven.
• Is calcitonin-receptor activation necessary for efficacy? If a purely AMY1R-selective agent matches broad agonists on weight reduction, it would suggest the calcitonin component is not required for the core effect. This has not been established.
• Does selective AMY1R agonism produce a distinct physiological response? Different receptor complexes have different tissue distributions and downstream signaling, so selectivity could in principle alter effects on gastric emptying, glucose handling, or other measures. Whether it does in humans is unknown.
• How well does it complement incretin therapy? Eloralintide's combination work with tirzepatide asks whether a selective amylin agonist adds cleanly to a dual incretin agonist, and the question has now advanced into phase 3 with ENLIGHTEN-6, which tests eloralintide in people already on weekly incretin therapy. Results will inform whether selectivity matters in combination as well as alone.

These are open questions, labeled as such. Eloralintide's scientific value lies partly in the answers it may eventually provide about amylin receptor biology, independent of how it performs commercially.

12. Which Compound Is "Better"?

There is no defensible way to declare a winner, because the answer depends entirely on what is being measured. On receptor selectivity, eloralintide is the more targeted molecule and the better tool for asking mechanistic questions. On clinical maturity, cagrilintide remains ahead, with completed phase-3 CagriSema trials and a filed regulatory application under FDA review, while eloralintide has only recently entered phase 3 and does not yet have phase-3 efficacy results. On combination research, both are active, cagrilintide with semaglutide and eloralintide with tirzepatide, and neither has clearly outrun the other. On existing human data, cagrilintide simply has more of it. On mechanistic novelty, eloralintide's selective design is the more distinctive.

Without a direct head-to-head trial, any claim that one compound is superior overall would be speculation dressed as a conclusion. The honest summary is that they are two credible but different bets on the amylin pathway: a selective agonist still proving its hypothesis, and a broad agonist that has already reached late-stage trials as part of a combination product.

13. The Future of Amylin-Based Research

Both compounds sit inside a larger shift in metabolic research toward pathways beyond GLP-1. After a decade in which GLP-1 and GLP-1-containing multi-agonists dominated, amylin has emerged as the most prominent non-GLP-1 axis, and the field is moving in a few clear directions.

The most active is amylin plus GLP-1 combination, exemplified by CagriSema and by eloralintide's combination work with tirzepatide, and extended by unimolecular peptides that combine amylin and GLP-1 activity in a single molecule. Lilly has moved this strategy into phase 3 with ENLIGHTEN-6, which is evaluating eloralintide in people with persistent obesity already receiving weekly incretin therapy. Alongside it, interest in selective amylin receptor agonists like eloralintide reflects a broader move from broad-spectrum to targeted design, as researchers try to separate the useful receptor activities from the rest. Longer-acting analogues and multi-pathway metabolic strategies continue to be explored, and several relevant trials, including cardiovascular-outcome and longer-duration studies in the cagrilintide program, were still ongoing as of this review. What the amylin class still lacks, relative to GLP-1 agents, is long-term outcome data; building that evidence base is the field's next task. The trajectory is clear enough, but it remains evidence-limited, and near-term readouts will shape it substantially.

14. Limitations of This Comparison

Comparing a phase-2 selective agonist against a phase-3 broad agonist studied mainly in combination requires particular caution. The following limitations apply to essentially every "eloralintide vs cagrilintide" comparison, including this one.

References

1. Coskun T, et al. "Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept." Molecular Metabolism. 2025. PubMed 41109426; PMC12640043.
2. Bhattachar SN, et al. "Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept." Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70439.
3. "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial." The Lancet. 2025; presented at ObesityWeek 2025. Lancet abstract. Trial registration: ClinicalTrials.gov NCT06230523.
4. Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in adults with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial." The Lancet. 2021;398(10317):2160–2172. doi:10.1016/S0140-6736(21)01751-7.
5. Garvey WT, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)." New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2502081; presented at the American Diabetes Association 85th Scientific Sessions, 2025.
6. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. "Amylin: pharmacology, physiology, and clinical potential." Pharmacological Reviews. 2015;67(3):564–600. doi:10.1124/pr.114.009621.
7. Novo Nordisk A/S. "Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management." Company announcement, December 2025. Regulatory status is current as of this review and should be reverified against the latest FDA and company communications.
8. Eli Lilly and Company. "Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight." Press release, 2025. Figures cited from company and congress reports; verify against the final peer-reviewed publication.